Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder

Bibliography

• SCAHILL L, SCHWAB-STONE M: Epidemiology of ADHD in school-age children. Child Adolesc. Psychiatr. Clin. N. Am. (2000) 9:541–555.
   PubMed Web of Science ®Google Scholar
• WEISS G, HECHTMAN L, MILROY T et al: Psychiatric status of hyperactives as adults: a controlled prospec-tive 15-year follow-up of 63 hyperactive children. J Am. Acad. Child Adolesc. Psychiatry (1985) 24:211–220.
   Web of Science ®Google Scholar
• •A hallmark study that confirmed the persistence of ADHD symptoms into adulthood.
   Google Scholar
• CONNERS CK, JETT JL: Attention Deficit Hyperactivity Disorder (in adults and children). Compact Clinicals, Kansas City, Missouri, USA (1999).
   Google Scholar
• BIEDERMAN J: Attention-deficit/hyperactivitydisorder: a life-span perspective. J Clin. Psychiatry (1998) 59 (Suppl. 7):4–16.
   Google Scholar
• BIEDERMAN J, FARAONE S, MILBERGER S et al.: Predic-tors of p ersistence and remission of ADHD into adoles-cence: results from a four-year prospective follow-up study. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:343–351.
   PubMed Web of Science ®Google Scholar
• SPENCER T, BIEDERMAN J, WILENS TE et al: Adults withattention-deficit/hyperactivity disorder: a controver-sial diagnosis. J. Clin. Psychiatry (1998) 59 (Suppl. 7):59–68.
   Google Scholar
• SILVER LB: Attention-deficit/hyperactivity disorder inadult life. Child Adolesc. Psychiatr. Clin. N Am. (2000) 9:511–523.
   PubMed Web of Science ®Google Scholar
• CASTELLANOS FX, GIEDD JN, MARCH WL et al.: Quantita-tive brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry (1996) 53:607–616.
   PubMed Web of Science ®Google Scholar
• SWANSON J, CATELLANOS FX, MURIAS M etal.: Cognitiveneuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curt-. Opin. Neurobiol (1998) 8:263–271.
   Google Scholar
• FILIPEK PA: Neuroimaging in the developmentaldisorders: the state of the science. J Child Psycho]. Psychiatr. (1999) 40:113–128.
   PubMed Web of Science ®Google Scholar
• ELIA J, AMBROSINI PJ, RAPOPORT JL: Treatment ofattention-deficit/hyperactivity disorder. N Eng]. J. Med. (1999) 340:780–788.
   PubMed Web of Science ®Google Scholar
• THAPAR A, HOLMES J, POULTON K et al.: Genetic basis ofattention deficit and hyperactivity. Br. J Psychiatry (1999) 174:105–111.
   PubMed Web of Science ®Google Scholar
• JENSEN PS: ADHD: current concepts on etiology, pathophysiology and neurobiology. Child Adoles. Psychiatr. Clin. N Am. (2000) 9:557–572.
   PubMed Web of Science ®Google Scholar
• SMALLEY SL, MCGOUGH JJ, DEL'HOMME Metal.: Familial clustering of symptoms and disruptive behaviors in multiplex families with attention-deficit/hyperac-tivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:1135–1143.
   Google Scholar
• COOK EH, STEIN MA, KRASOWSKI MD et al.: Association of attention deficit disorder and the dopamine transporter gene. Am]. Hum. Genet. (1995) 56:993–998.
   PubMed Web of Science ®Google Scholar
• GILL M, DALY G, HERON S, HAWI Z, FITZGERALD M: Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry (1997) 2:311–313.
   PubMed Web of Science ®Google Scholar
• LAHOSTE GJ, SWANSON JM, WIGAL SB et al.: Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry (1996) 1:121–124.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, BIEDERMAN J, WEIFFENBACH B et al.: Dopamine at gene 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry (1999) 156:768–770.
   PubMed Web of Science ®Google Scholar
• MURPHY P, SCHACHAR R: Use of self-ratings in theassessment of symptoms of attention deficit hyperac-tivity disorder in adults. Am. J. Psychiatry (2000) 157:1156–1159.
   PubMed Web of Science ®Google Scholar
• ZAMETKIN AJ, ERNST M: Problems in the managementof attention-deficit-hyperactivity disorder. N Engl. J Med. (1999) 340:40–46.
   PubMed Web of Science ®Google Scholar
• CONNERS CK: Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J. Clin. Psychiatry (1998) 59 (Suppl. 7):24–30.
   Google Scholar
• WARD MF, WENDER PH, REIMHERR FW: The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit disorder. Am. J. Psychiatry (1993) 150:885–890.
   PubMed Web of Science ®Google Scholar
• BROWN T: Brown Attention Deficit Disorder Scales: Manual. Psychological Corporation, San Antonio, Texas, USA (1996).
   Google Scholar
• DUPAUL G: The ADHD Rating Scale: Normative Data, Reliability and Validity. University of Massachusetts Medical School, Worcester, Massachusetts, USA (1990).
   Google Scholar
• CONNERS CK: Conners Adult Attention-Deficit Rating Scale. Multi-Health Systems, North Tonawanda, New York, USA (1998).
   Google Scholar
• WALDMAN ID, ROWE DC, ABRAMOWITZ A et al.: Associa-tion and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. (1998) 63:1767–1776.
   PubMed Web of Science ®Google Scholar
• SWANSON JM, FLODMAN P, KENNEDY J et al.: Dopamine genes and AMID. Neurosci. Biobehav. Rev. (2000) 24:21–25.
   PubMed Web of Science ®Google Scholar
• •An excellent summary of the genetic studies involving dopamine and its relationship to ADHD.
   Google Scholar
• DOUGHERTY DD, BONAB AA, SPENCER TJ, RAUCH SL,MADRAS BK, FISCHMAN AJ: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet (1999) 354(9196):2132–2133.
   PubMed Web of Science ®Google Scholar
• MTA CO-OPERATIVE GROUP: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56:1073–1086.
   PubMedGoogle Scholar
• ••Of great historical importance, this large, well-crafted studyconfirmed the primacy of stimulant medication for ADHD, at least in younger individuals.
   Google Scholar
• STUBBE DE: Attention-deficit/hyperactivity disorderoverview. Child Adolesc. Psychiatr. Clin. N Am. (2000) 9:469–479.
   PubMed Web of Science ®Google Scholar
• MTA CO-OPERATIVE GROUP: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56 :1088–1096.
   PubMedGoogle Scholar
• WILENS TE, SPENCER TJ: The stimulants revisited. ChildAdolesc. Psychiatr. Clin. N Am. (2000) 9:573–603.
   PubMed Web of Science ®Google Scholar
• •A good overall review of the pharmacokinetic, pharmacody-namic and practical clinical aspects of the stimulants.
   Google Scholar
• SPENCER T, BIEDERMAN J, WILENS T et al: Pharmaco- therapy of attention-deficit hyperactivity disorder across the life cycle./ Am. Acad. Child Adolesc. Psychiatry (1996) 35:409–432.
   PubMed Web of Science ®Google Scholar
• •A dated but important summary of the phenomenology of adult ADHD and the evidence-based support for various pharmacotherapeutic approaches to this disorder.
   Google Scholar
• CLURE C, BRADY KT, SALADIN ME, JOHNSON D, WAID R,RITTENBURY M: Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am. J. Drug Alcohol Abuse (1999) 25:441–448.
   PubMed Web of Science ®Google Scholar
• DOWNEY KK, STELSON FW, POMERLEAU OF, GIORDANIB: Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. J Nerv. Ment. Dis. (1997) 185:32–38.
   PubMed Web of Science ®Google Scholar
• BRAMBLE D: Psychostimulants and psychiatrists: theTrent Adult Psychiatry Psychostimulant Survey. J. Psychopharmacol. (2000) 14:67–69.
   PubMedGoogle Scholar
• POPPER CW: Pharmacologic alternatives topsychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. (2000) 9:605–646.
   PubMed Web of Science ®Google Scholar
• ARNOLD LE: Methylphenidate vs. amphetamine:comparative review. J Attention Disord. (2000)3:200–211.
   Google Scholar
• PLISZKA SR, GREENHILL LL, CRISMON ML et al: The Tex asChildren's Medication Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part II: tactics. Attention-deficit/hyperac-tivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:920–927.
   PubMed Web of Science ®Google Scholar
• SWANSON J, GUPTA S, GUINTA D et al: Acute toleranceto methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol. Ther. (1999) 66:295–305.
   PubMed Web of Science ®Google Scholar
• •An intriguing study that prompted a revaluation of the optimal dose-response strategies for the most effective prescribing of stimulants, such as methylphenidate.
   Google Scholar
• SWANSON J, GREENHILL L, WIGAL S et al.: Pharmacoki-netic and pharmacodynamic properties of ampheta-mine in ADHD children. Scientific proceedings of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Chicago, Illinois, USA (1999). Abstract NR–177.
   Google Scholar
• WILENS TE: long-term efficacy and safety of Concerta(OROS methylphenidate HCL) extended release Tablets. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry New York City, USA (2000). Abstract 64C.
   Google Scholar
• GREENHILL LL, HALPERIN JM, ABIKOFF H: Stimulantmedications. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:503–512.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ et al: Controlledtrial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder./ Clin. Psycho-pharmacol (1999) 19:257–264.
   PubMedGoogle Scholar
• CASTANEDA R, LEVY R, HARDY M, TRUJILLO M: long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr. Serv. (2000) 51:169–171.
   PubMed Web of Science ®Google Scholar
• MARGOLIN A, AVANTS SK, KOSTEN TR: Pemoline for thetreatment of cocaine dependence in methadone maintained patients. J. Psychoactive Drugs (1996) 28:301–304.
   PubMed Web of Science ®Google Scholar
• HORRIGAN JP, BARNHILL LJ: low-dose amphetaminesalts and adult attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2000) 61:414–417.
   PubMed Web of Science ®Google Scholar
• SPENCER T, WILENS T, BIEDERMAN J, KAGAN J,BEARMAN S: Pharmacodynamics of Adder all in adults with attention-deficit/hyperactivity disorder. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P32.
   Google Scholar
• MCGOUGH JJ, GREENHILL L, BIEDERMAN J et al.: PK/PDanalyses of 5LI381 in pediatric ADHD. Abstract P40, scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000).
   Google Scholar
• PATRICK KS, STRAUGHN AB, JARVI EJ, BREESE GR,MEYER MC: The absorption of sustained-release methylphenidate formulation compared to an immediate-release formulation. Biopharm. Drug Dispos. (1989) 10:165–171.
   PubMed Web of Science ®Google Scholar
• PELHAM WE, GREENSLADE KE, VODDE-HAMILTON M etal.: Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine and pemoline. Pediatrics (1990) 86:226–237.
   Google Scholar
• PATERSON R, DOUGLAS C, HALLMAYER J, HAGAN M, KRUPENIA Z: A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust. NZ. J Psychiatry (1999) 33:494–502.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, RUSSO J: Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc. Psychopharmacol. (2000) 10:311–320.
   PubMed Web of Science ®Google Scholar
• GREENHILL LL, ELLIOTT GR, SWANSON JM, WILENS TE, JENSEN P: Development of new long-duration stimulant for ADHD:Alza's Concerta. Scientific proceed-ings of the 47th Annual Meeting of theAmerican Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract S64.
   Google Scholar
• MODI NB, LINDEMULDER B, GUPTA SK: Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HC1) formulation. J. Clin. Pharmacol (2000) 40:379–388.
   PubMed Web of Science ®Google Scholar
• SWANSON JM: Development and clinical trial testing of Concerta for the treatment of ADHD in children. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract 64B.
   Google Scholar
• GREENHILL LL: Once-daily, methylphenidate modified-release (MPH MR) treatment of attention-deficit/hyperactivity disorder (ADHD). Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P34.
   Google Scholar
• QUINN D: Methylphenidate: the role of the d-isomer. In: Ritalin: Theory and Practice. Greenhill L, Osman B (Eds.), Mary Ann Liebert, New York, USA (1999):369–374.
   Google Scholar
• WILENS TE, BIEDERMAN J, PRINCE J et al.: Six-week,double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am. J. Psychiatry (1996) 153:1147–1153.
   PubMed Web of Science ®Google Scholar
• LEONARD HL, MEYER MC, SWEDO SC et al.: Electrocar-diographic changes during desipramine and clomipramine treatment in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:1460–1468.
   PubMed Web of Science ®Google Scholar
• POPPER CW, ZIMNITZKY B: Sudden death putatively related to desipramine treatment in youth: a fifth case and a review of speculative mechanisms. J Child Adolesc. Psychopharmacol (1995) 5:283–300.
   Google Scholar
• WENDER PH, REIMHERR FW: Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am. J. Psychiatry (1990) 147:1018–1020.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN MG: Bupropion sustained release and smoking cessation. J Clin. Psychiatry (1998) 59 (Suppl. 4):66–72.
   Google Scholar
• DUNNER DL, ZISOOK S, BILLOW AA, BATEY SR, JOHNSTON JA, ASCHER JA: A prosp ective safety surveil-lance study for bupropion sustained release in the treatment of depression. J. Clin. Psychiatry (1998) 59:366–373.
   PubMed Web of Science ®Google Scholar
• WILENS T, SPENCER T, BIEDERMAN J et al.: A controlledtrial of bupropion SR for attention deficit hyperac-tivity disorder in adults. Scientific proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit Program of the NIMH. Boca Raton, Florida, USA (1999). Poster Abstract 29.
   Google Scholar
• SWANSON J, SALEM, WEBSTER C, LAURENZA A, ASGHAR-NEJAD M: Pediatric pharmacokinetics/pharmacody- n am icsofGW32 065 9inattention-deficit/hyperactivity disorder (ADHD). Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P28.
   Google Scholar
• DEVEAUGH-GEISS J, CONNERS CK, SARKIS E et al.: Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder. Abstract P29, scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000).
   Google Scholar
• LEAKE CD: The Amphetamines. Charles C. Thomas, Spring-field, Illinois, USA (1958):3–18.
   Google Scholar
• ••A detailed summary dating back more than four decadesthat offers valuable scientific and clinical data that is only now being rediscovered by investigators of drug therapies for ADHD.
   Google Scholar
• GOLDEN RN, NICHOLAS L: Antidepressant efficacy ofvenlafaxine. Depress. Anxiety (2000) 12 (Suppl. 0:45–49.
   Google Scholar
• ROSEBOOM PH, KALIN NH: Neuropharmacology of venlafaxine. Depress. Anxiety (2000) 1 2 (Suppl. 0:20–29.
   Google Scholar
• HEDGES D, REIMHERR FW, ROGERS A, STRONG R, WENDER PH: An open trial of venlafaxine in adults patients with attention deficit hyperactivity disorder. Psychopharmacol. Bull. (1995) 31 :779–783.
   PubMed Web of Science ®Google Scholar
• ADLER LA, RESNICK S, KUNZ M, DEVINSKY O: Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol. Bull. (1995) 31 :785–788.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ: Venlafaxine in adults with attention-deficit/hyperac-tivity disorder: an open clinical trial. J. Clin. Psychiatry (1996) 57:184–189.
   PubMed Web of Science ®Google Scholar
• DALLAL A, CHOUINARD G: Withdrawal and reboundsymptoms associated with abrupt discontinuation of venlafaxine.j Clin. Psychopharmacol. (1998) 18:343–344.
   PubMedGoogle Scholar
• MACKAY FR, DUNN NR, MARTIN RM eta].: Newer antide-pressants: a comparison of tolerability in general practice. Br. J. Gen. Pract (1999) 49:892–896.
   PubMedGoogle Scholar
• HEILIGENSTEIN JH, SPENCER TJ, FARIES DE, BIEDERMAN J, KRATOCHVIL C, CONNERS CK: Efficacy of tomoxetine vs. placebo in pediatric outpatients with ADHD. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P11.
   Google Scholar
• SPENCER T, BIEDERMAN J, WILENS T et al.: Effectivenessand tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J Psychiatry (1998) 155:693–695.
   PubMed Web of Science ®Google Scholar
• REIDERER P, REYNOLDS GP: Deprenyl is a selective inhibitor of brain MAO-Bin the long-term treatment of Parkinson's disease. Br. J Clin. Pharmacol. (1980) 9:98–99.
   PubMed Web of Science ®Google Scholar
• SZOKO E, KALASZ H, MAGYAR K: Biotransformation of deprenyl enantiomers. Eur. J. Drug Metab. Pharma-cokinet (1999) 24:315–319.
   PubMed Web of Science ®Google Scholar
• ERNST M, LIEBENAUER LL, TEBEKA D et al.: Selegiline in ADHD adults: plasma monoamines and monoamine metabolites. Neuropsychopharmacol. (1997) 16:276–284.
   PubMed Web of Science ®Google Scholar
• HEINONEN EH, MYLLYLA V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Sal (1998) 19:11–22.
   PubMed Web of Science ®Google Scholar
• DALLO J, YEN TT, KNOLL J: The aphrodisiac effect of (-)deprenyl in male rats. Acta Physiol. Hung. (1990) 75 (Suppl.):75–76.
   Google Scholar
• MAHMOOD I: Clinical pharmacokinetics and pharma-codynamics of selegiline: an update. Clin. Pharma-cokinet. (1997) 33:91–102.
   PubMed Web of Science ®Google Scholar
• ROHATAGI S, BARRETT JS, DEWITT KE, MORALES RJ: Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm. Drug Dispos. (1997) 18:567–584.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST MA, JACKSON WJ, TERRY AV, DECKER MW, ARNERIC SP, BUCCAFUSCO JJ: Central nicotinic receptor agonists ABT-418, ABT-089 and (-)-nicotine reduce distractibility in adult monkeys. Psychopharma-cology (Bed.) (1998) 1 3 6:50–58.
   Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ et al.: A pilotcontrolled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J Psychiatry (1999) 156:1931–1937.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO H, YAMANISHI Y, IIMURA Y, KAWAKAMI Y:Donepezil hydrochloride (E2020) and other acetyl-cholinesterase inhibitors. CUIT. Med. Chem. (2000) 7:303–339.
   PubMed Web of Science ®Google Scholar
• GREENBERG SM: Donepezil in the treatment of Alzheimer's disease. Arch. Neurol. (2000) 57:1380.
   PubMedGoogle Scholar
• KISHNANI PS, SPIRIDIGLIOZZI GA, HELLER JH et al.: Donepezil for Down's syndrome. Am. J Psychiatry (2001) 1 5 8: 143.
   Google Scholar
• WHELAN FJ, WALKER MS, SCHULTZ SK: Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann. Clin. Psychiatry (2000) 12:131–135.
   PubMedGoogle Scholar
• HOOPES SP: Donepezil for Tourette's disorder and ADM. J. Clin. Psychopharmacol (1999) 1 9:381–382.
   Google Scholar
• WILENS TE, BIEDERMAN J, WONG J, SPENCER TJ, PRINCE JB: Adjunctive donepezil in attention deficit hyperac-tivity disorder in youth: case series. J Child Adolesc. Psychopharmacol. (2000) 10:217–222.
   PubMed Web of Science ®Google Scholar
• BROUGHTON RJ, FLEMING JA, GEORGE CF et al.: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology (1997) 49:444–451.
   PubMed Web of Science ®Google Scholar
• SCATES AC, DORAISWAMY PM: Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother. (2000) 34:1302–1312.
   PubMed Web of Science ®Google Scholar
• GARATTINI S: Pharmacology of amineptine, an antide-pressant agent acting on the dopaminergic system: a review. Int. Clin. Psychopharmacol. (1997) 1 2 (Suppl. 3):515–519.
   Google Scholar
• MONTEJO AL, LLORCA G, IZQUIERDO JA et al.: Sexual dysfunction with antidepressant agents: effect of the change to amineptine in patients with sexual dysfunc-tion secondary to SSRIs. Actas. Esp. Psiquiatr. (1999) 27:23–34.
   PubMedGoogle Scholar
• GIOVANNINI MG, BARTOLINI L, BACCIOTTINI L, GRECO L, BLANDINA P: Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav. Brain Res. (1999) 104:147–155.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ, PRINCE J: Pharmacotherapy of adult attention deficit/hyperac-tivity disorder: a review. J. Clin. Psychopharmacol (1995) 15:270–279.
   PubMed Web of Science ®Google Scholar
• http://www.boston1ifesciences.com/news41.htm
   Google Scholar
• http://www.shiregroup/com/4_rd/401_rd_cns03.html
   Google Scholar
• http://www.celltechgroup.com/company_information/pre ss_releases/celltech_grou.../021100.htm
   Google Scholar
• http://www.noven.com/PR030200.htm
   Google Scholar
• h ttp : //www .biosp ace . co m/news_story .cfm?StoryId = 1108604
   Google Scholar
• http://www.findarticles.com/m0FQN/2000_Feb_28/596139 10/pl/article.jhtml
   Google Scholar
• http://www.biospace.com/ct/detail.cfm?ClinicalID = 182304
   Google Scholar
• http://www.pslgroup.com/dg/1db532.htm
   Google Scholar
• http://www.gliatech.com/pages/drug-development/index. html
   Google Scholar
• http://www.centerwatch.com/patient/studies/stu 1920521.ht ml
   Google Scholar
• http://www.cortexpharm.com/html/news/04-19-00.html
   Google Scholar
• http://www.shiregroup.com/4_rd/401_rd_cns04.html
   Google Scholar